View Older Stories View More Recent Stories

May 10, 2018 07:00AM Resverlogix Announces Lifting by TSX of Review
May 7, 2018 07:00AM Resverlogix Closes US$30 Million Loan
May 1, 2018 07:00AM Resverlogix Advances US$30 Million Loan Closing Documentation
Apr 12, 2018 07:00AM Resverlogix Announces TSX Review Update
Apr 11, 2018 07:00AM Resverlogix Announces US$30 Million Loan Commitment Letter
Mar 28, 2018 07:00AM Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease
Mar 19, 2018 07:00AM Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial
Feb 26, 2018 07:00AM Resverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Feb 8, 2018 07:00AM Resverlogix Highlights Key Accomplishments and 2018 Targets
Jan 11, 2018 09:33AM Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
Jan 8, 2018 08:57AM Resverlogix and Medison Pharma Ltd. Announce Strategic Licensing Agreement
Dec 14, 2017 07:27PM Resverlogix Announces Filing of Quarterly Financial Statements and Management’s Discussion & Analysis
Dec 12, 2017 08:08PM Resverlogix Announces Voting Results From The 2017 Annual Meeting Of Shareholders
Dec 12, 2017 07:30AM Nature’s Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1
Dec 6, 2017 07:16PM Resverlogix Repays $68.8 Million Loan
Dec 4, 2017 07:00AM Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
Nov 2, 2017 08:00AM Resverlogix Announces Participation in Upcoming Conferences
Nov 1, 2017 08:00AM Resverlogix Announces Fifth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Oct 13, 2017 09:27AM Resverlogix Announces $87 Million Private Placement with Shenzhen Hepalink
Oct 2, 2017 06:20PM Resverlogix Announces Annual and Special Meeting of Shareholders
Sep 13, 2017 06:41PM Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
Sep 5, 2017 07:00AM Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
Aug 29, 2017 12:56PM Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial
Aug 28, 2017 07:00AM Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction
Jul 25, 2017 06:30PM Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017
Jul 25, 2017 09:00AM Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
Jul 10, 2017 07:00AM Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
Jun 28, 2017 07:00AM Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Jun 5, 2017 06:55AM Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
May 31, 2017 07:00AM Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain
May 30, 2017 07:00AM Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
May 23, 2017 07:00AM Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
May 15, 2017 09:35AM Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
Mar 17, 2017 07:00AM Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities
Mar 15, 2017 07:00AM Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
Feb 23, 2017 07:00AM Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial
Feb 13, 2017 07:00AM Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease
Jan 23, 2017 07:00AM Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
Jan 5, 2017 05:43PM Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA
Dec 15, 2016 11:24PM Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders
Dec 13, 2016 06:28PM Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
Dec 5, 2016 12:13PM Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
Nov 17, 2016 08:00AM Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies
Oct 6, 2016 06:15PM Resverlogix Announces Annual and Special Meeting of Shareholders
Oct 4, 2016 07:00AM Resverlogix To Host Research & Development Update Featuring Key Opinion Leaders in Cardiovascular and Renal Disease
Sep 14, 2016 06:35PM Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
Sep 12, 2016 07:00AM Resverlogix Announces Participation in Upcoming Conferences
Aug 29, 2016 11:03AM Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
Aug 29, 2016 11:03AM Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
Aug 11, 2016 07:00AM Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
View More Recent Stories View Older Stories